11 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 6 Phase 3, 5 Phase 2, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Not yet recruiting 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 1 | Terminated 1 |
Follow Lamivudine (3TC): new trials by email Literature Review of Lamivudine (3TC) trials Research Report on Lamivudine (3TC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC) - HIV Infection | Phase 3 | Not yet recruiting | University College, London | 800 | 2026-11-01 | 2026-08-28 |
| A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058) Islatravir (ISL), Lamivudine (3TC) - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 20 | 2024-02-07 | 2025-02-06 |
| Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome Abacavir (ABC), Lamivudine (3TC), Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT) - Aicardi-Goutières Syndrome | Phase 2 | Completed | University of Edinburgh | 13 | 2022-08-24 | 2024-05-09 |
| 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor Dolutegravir (DTG), Lamivudine (3TC), Rilpivirine (RPV) - HIV Infections | Completed | ViiV Healthcare | 774 | 2019-11-18 | 2025-01-22 | |
| Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept. Dolutegravir (DTG), Lamivudine (3TC) - HIV-1-infection | Phase 2 | Unknown | Instituto de Investigación Hospital Universitario La Paz | 41 | 2017-11-02 | 2020-07-07 |
| An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1) Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC) - Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | Completed | ViiV Healthcare | 719 | 2016-07-21 | 2023-08-24 |
| An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2) Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC) - Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | Completed | ViiV Healthcare | 722 | 2016-07-18 | 2023-12-07 |
| Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy HAART regimen, 3TC or FTC monotherapy - HIV Disease | Phase 4 | Terminated | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 33 | 2011-03-01 | 2015-11-13 |
| Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding lopinavir/ritonavir (LPV/r), Lamivudine (3TC) - HIV Infections | Phase 3 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | 1500 | 2009-12-01 | 2014-04-14 |
| Pharmacokinetics of Lamivudine at Two Different Doses Lamivudine (3TC) - HIV Infections | Phase 1 / Phase 2 | Completed | Kirby Institute | 24 | 2009-12-01 | 2011-02-11 |
| Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME) Efavirenz (EFV), Lamivudine (3TC), Didanosine (ddI) - HIV Infections, AIDS | Phase 2 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | 52 | 2006-02-01 | 2011-12-05 |
| Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN) Structured Treatment Interruption, Zidovudine (ZDV), Lamivudine (3TC) - HIV Infections | Phase 3 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | 840 | 2002-12-01 | 2008-12-30 |
| Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women Nevirapine, Zidovudine (ZDV), Lamivudine (3TC) - HIV Infections | Phase 3 | Completed | Boehringer Ingelheim | 2648 | 1999-04-01 | 2014-07-14 |
| Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir Tipranavir (TPV), Ritonavir (RTV), Delavirdine (DLV) - HIV Infections | Phase 2 | Completed | Boehringer Ingelheim | 18 | 1999-03-01 | 2014-09-25 |
HIV Infections (10) · Acquired Immunodeficiency Syndrome (4) · Infections (2) · Breast Feeding (1)
French National Agency for Research on AIDS and Viral Hepatitis (3) · ViiV Healthcare (3) · Boehringer Ingelheim (2) · Instituto de Investigación Hospital Universitario La Paz (1) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group (1) · Kirby Institute (1) · Merck Sharp & Dohme LLC (1) · University College, London (1) · University of Edinburgh (1)
Spain (4) · United Kingdom (4) · United States (4) · Argentina (3) · Australia (2) · Belgium (2) · Burkina Faso (2) · Canada (2) · France (2) · Germany (2) · Italy (2) · Mexico (2) · Portugal (2) · Romania (2) · Russia (2)
Aboubacar Nacro, MD (1) · Allison L. Agwu, MD, Sc.M. (1) · Chipepo Kankasa, MD (1) · Christine Danel, MD (1) · Emmanuel Bissagnene, Pr (1) · James K Tumwine, MD, PhD (1) · Justus Hofmeyer, MD (1) · Marta Boffito, MD PhD (1) · Nicolas Meda, MD, PhD (1) · Philippe Msellati, MD, PhD (1) · Philippe Vande Perre, MD, PhD (1) · Roger Salamon, Pr (1)
PMID 34913844, PMID 16782488, PMID 18986246, PMID 20516271, PMID 21857286, PMID 23039034, PMID 23719348, PMID 26603917, PMID 27895016, PMID 28469697, PMID 28604824, PMID 30814028, PMID 31633158, PMID 31994250, PMID 32067040, PMID 32228542, PMID 32408111, PMID 32991450, PMID 36447613, PMID 40134635
2015 (1), 2016 (1), 2017 (1), U01AI068632 (1)